M.M. Arrebola
University of Málaga
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M.M. Arrebola.
Journal of Neuroscience Research | 2004
J.P. De La Cruz; A. Guerrero; José Antonio González-Correa; M.M. Arrebola; F. Sánchez de la Cuesta
Acetylsalicylic acid (ASA) reduces the incidence of ischemic stroke mainly through its antithrombotic action; however, it also has a direct neuroprotective effect. The present study was designed to evaluate the effect of ASA on oxidative stress and the activity of nitric oxide synthase (NOS) in an in vitro model of hypoxia in rat brain slices. Rat brain slices were perfused with nitrogen (hypoxia) for a maximum of 120 min, after which we measured lipid peroxidation, glutathione levels, glutathione‐related enzyme activities, and constitutive nitric oxide synthase (cNOS) and inducible nitric oxide synthase (iNOS) activities. In brain tissue subjected to hypoxia, ASA reduced oxidative stress and iNOS activity (all increased by hypoxia), but only when used at higher concentrations. The effects of salicylic acid (SA) were similar but more intense than were those of ASA. After oral administration, the effect of SA was much greater than that of ASA, and the decrease in cell death with SA was seen much more clearly. In view of the greater effect of SA compared to ASA on changes in oxidative stress parameters in a model of hypoxia, and higher brain concentrations of SA when it is administered alone than when ASA is given (undetectable levels), we conclude that SA plays an important role in the cytoprotective effect in brain tissue after ASA administration.
Journal of Cardiovascular Pharmacology | 2004
M.M. Arrebola; José Pedro De La Cruz; M.A. Villalobos; Araceli Pinacho; A. Guerrero; Felipe Sánchez de la Cuesta
Clopidogrel is an antiplatelet drug that belongs to the group of thienopyridines. Because of its main mechanism of action most studies of clopidogrel have centered on the platelet ADP pathway. The aim of the present study was to compare the effects of clopidogrel, ticlopidine, and aspirin, on platelet activation by collagen (the main inducer of platelet activation in vivo), prostanoid, and NO production, and the effects on blood perfusion experiments. Clopidogrel inhibited platelet aggregation induced in whole blood by collagen and TxB2 production to a greater extent than did ticlopidine. Prostacyclin synthesis did not change after incubation with thienopyridines, whereas aspirin inhibited synthesis in a dose-dependent manner. Thienopyridines increased NO production to a greater extent than did aspirin. All three drugs impaired the platelet-subendothelium interaction under flow conditions. With thienopyridines, the presence of endothelium did not modify the percentage of the surface coated by platelets.
Neuroscience Letters | 2004
A. Guerrero; José Antonio González-Correa; M.M. Arrebola; J. Muñoz-Marín; F. Sánchez de la Cuesta; J.P. De La Cruz
The aim of the present study was to analyze the relative participation of the antiplatelet and the antioxidant effects of acetylsalicylic acid (ASA) and salicylic acid (SA) after a single dose (1 or 10 mg/kg i.p.) in an in vitro model of anoxia in slices of rat brain. After 20 min of drug administration, blood and brain were obtained (n=6 rats per group). We measured: lipid peroxidation, glutathione levels and lactate dehydrogenase efflux (LDH), ASA and SA concentrations and platelet aggregation in whole blood. An increase in lipid peroxidation (80%) and in LDH efflux (520%) and a decrease in glutathione levels (35%) were observed after 120 min anoxia in saline-treated rats. SA reduced this oxidative stress and LDH efflux, but it did not modify platelet aggregation. ASA strongly inhibited platelet aggregation but exerted a poor antioxidant effect. ASA was not detectable in brain tissue. We conclude that repeated doses of ASA are necessary to obtain a tissular antioxidant effect, probably when liver generates enough SA.
Neuroscience Letters | 2010
José Pedro De La Cruz; Sergio Del Río; M.M. Arrebola; Juan Antonio López-Villodres; Nuria Jebrouni; José Antonio González-Correa
Aspirin is the most widely used drug for the secondary prevention of ischemic stroke in patients suffering from diabetes mellitus. Moreover virgin olive oil (VOO) administration exerts a neuroprotective effect in healthy rat brain slices. The aim of the present study was to determine the possible influence of VOO administration to streptozotocin-diabetic rats (DR) on the neuroprotective effect of aspirin in rat brain. DR were treated during 3 months with saline, aspirin (2mg/kg/day p.o.), VOO (0.5 mL/kg/day p.o.) or its association; a control normoglycemic group was treated with saline. Brain slices were subjected to oxygen-glucose deprivation before a reoxygenation period. All the treatments significantly reduced lactate dehydrogenase LDH efflux after reoxygenation (-54.1% for aspirin, -51.3% for VOO and -72.9% for aspirin plus VOO). Lipid peroxides in brain slices were also reduced after the treatment with aspirin (-17.90%), VOO (-37.3%) and aspirin plus VOO (-49.2%). Production of nitric oxide after reoxygenation was inhibited by all the treatments (-46.5% for ASA, -48.2% for VOO and -75.8% for ASA plus VOO). The activity of the inducible isoform (iNOS) was inhibited by the three types of treatment (-31.8% for ASA, -29.1% for VOO and -56.0% for ASA plus VOO). The main conclusion of our study is that daily oral administration of VOO to diabetic rats may be a natural way to increase the neuroprotective effect of aspirin in diabetic animals.
Anesthesiology | 2007
José Antonio González-Correa; M.M. Arrebola; Eva Martín-Salido; J. Muñoz-Marín; Felipe Sánchez de la Cuesta; José Pedro De La Cruz
Background:The aim of the current study is to evaluate the antiplatelet effect of dexibuprofen in healthy volunteers in comparison with low-dose aspirin. Methods:Healthy volunteers (n = 12) were treated in a crossover manner with 100 mg daily aspirin or with 800 mg daily dexibuprofen. Blood samples were obtained within 24 h; 3, 7, and 14 days after repeated doses; and 24 h after the last dose. In each sample, the authors measured platelet aggregation, thromboxane B2, 6-keto-prostaglandin F1α, and nitric oxide. Results:The antiplatelet effect of dexibuprofen (maximal inhibition of aggregation was 48–55% for adenosine diphosphate and 90–95% for collagen and arachidonic acid) was equal to the effect of aspirin. The main difference between the two drugs was in the degree of recovery of platelet function. The effect of aspirin persisted for 24 h after the last dose (remaining inhibition 50%, respect to the pretreatment value), whereas platelet aggregation had returned to baseline pretreatment values within 24 h after dexibuprofen was stopped. Conclusions:Both aspirin and dexibuprofen inhibited platelet function with a similar intensity, but dexibuprofen exerted a reversible effect for 24 h after the last dose.
Platelets | 2005
José Antonio González-Correa; M.M. Arrebola; A. Guerrero; J. Muñoz-Marín; D. Ruiz-Villafranca; F. Sánchez de la Cuesta; J.P. De La Cruz
We analysed the in vitro interaction between acetylsalicylic acid and vitamin E on the principal antiplatelet sites of action of acetylsalicylic acid, i.e., platelet aggregation, prostanoid production in platelets and leukocytes, and nitric oxide synthesis. Aggregation was measured in whole blood and in platelet-rich plasma (PRP) with ADP, collagen or arachidonic acid as platelet inducers, and we measured the production of thromboxane B2, prostacyclin and nitric oxide. Vitamin E potentiated the antiplatelet effect of acetylsalicylic acid in both whole blood and PRP. In PRP induced with collagen the IC50 for acetylsalicylic acid alone was 339 ± 11.26, and that of acetylsalicylic acid + vitamin E was 0.89 ± 0.09 (P < 0.05). Vitamin E did not enhance inhibition of platelet thromboxane production by acetylsalicylic acid. Vitamin E spared or even increased prostacyclin levels, and acetylsalicylic acid + vitamin E diminished the inhibition of prostacyclin synthesis by acetylsalicylic acid (IC50 acetylsalicylic acid alone = 1.81 ± 0.15 µM; IC50 acetylsalicylic acid + vitamin E = 12.92 ± 1.10 µM, P < 0.05). Vitamin E increased the effect of acetylsalicylic acid on neutrophil nitric oxide production 42-fold (P < 0.05). We conclude that vitamin E potentiates the antiplatelet effect of acetylsalicylic acid in vitro, and thus merits further research in ex vivo studies.
Brain Research | 2004
José Antonio González-Correa; M.M. Arrebola; I.M. Ureña; A. Guerrero; J. Muñoz-Marín; D. Ruiz-Villafranca; F. Sánchez de la Cuesta; J.P. De La Cruz
Acetylsalicylic acid (ASA) is the most widely used drug in the prevention of ischemic vascular accidents, mainly because of its antithrombotic effect. Recently, evidence of a neuroprotective effect has appeared. The aim of this study was to evaluate the neuroprotective effect of triflusal, a fluorinated derivative of ASA, in a model of anoxia-reoxygenation in rat brain slices. Rats (n=10 per group) were treated for 7 days with 1, 10 or 50 mg/kg/day p.o. of triflusal or ASA or solvent (control group), then brain slices were obtained and subjected to a period of anoxia followed by 180 min of reoxygenation. We measured oxidative stress parameters (lipid peroxidation, glutathione system), prostaglandins (PGE(2)), nitric oxide pathway activity (NO) (nitrites+nitrates, constitutive and inducible NO synthase activity) and cell death (lactate dehydrogenase (LDH) efflux). Triflusal decreased cell death in rat brain slices subjected to reoxygenation after anoxia by 21%, 42% and 47% with 1, 10 and 50 mg/kg/day, respectively. This effect was proportionately greater than the effect of ASA (0%, 25% and 24%). The antioxidant effects of triflusal on the biochemical mechanisms of cell damage studied here were also greater than the effects of ASA: lipid peroxidation was reduced by 29%, 35% and 36% with triflusal, and 0%, 19% and 29% with ASA. Inducible NO synthase activity was reduced by 25%, 27% and 30% with triflusal, and 0%, 25% and 24% with ASA. Triflusal can be considered an alternative to ASA as a neuroprotective agent, at least in the experimental model of anoxia-reoxygenation used in the present study.
Neuroscience Letters | 2006
José Antonio González-Correa; M.M. Arrebola; A.L. Cansino; J. Muñoz-Marín; A. Guerrero; F. Sánchez de la Cuesta; J.P. De La Cruz
Diabetes mellitus is a risk factor for cerebrovascular ischemic disease. Aspirin (acetylsalicylic acid) is the most widely used drug for the secondary prevention of thrombotic phenomena. It has been also recently demonstrated that alpha-tocopherol influenced in vitro the antiplatelet effect of aspirin. The aim of the present study is to evaluate the effects aspirin plus alpha-tocopherol on cerebral oxidative stress, prostaglandin production and the nitric oxide pathway in a model of hypoxia-reoxygenation in rat brain slices. Our results show an imbalance in brain oxidative status (reflected mainly as the increase in lipid peroxides) as a result of diabetes itself rather than a failure of the glutathione-based antioxidant system. Moreover, our results also show a higher concentration of prostaglandins in the brain of diabetic animals and a higher nitric oxide concentration, mainly through a high iNOS activity. After 180 min of post-hypoxia reoxygenation, LDH activity was 40.6% higher in animals with diabetes, in comparison to non-diabetic animals. The increase of the LDH efflux observed in non-treated rats was reduced by 31.2% with aspirin, by 34.7% with alpha-tocopherol and by 69.8% with the association aspirin-alpha-tocopherol. The accumulation of prostaglandin E2 observed in diabetic non-treated rats was reduced statistically after the treatment with aspirin (34.2% inhibition), alpha-tocopherol (19.3% inhibition) or the association aspirin-alpha-tocopherol (54.4% inhibition). Nitric oxide production after 180 min reoxygenation was significantly reduced in aspirin (36.4%), alpha-tocopherol (22.7%) and aspirin-alpha-tocopherol (77.8%) treated rats with respect to diabetic non-treated animals; this was related mainly with a reduction in iNOS activity. The association between aspirin and alpha tocopherol could protects against brain ischemic-reperfusion damage with a better profile than aspirin alone.
British Journal of Pharmacology | 2002
J.P. De La Cruz; M.A. Villalobos; R. Escalante; A. Guerrero; M.M. Arrebola; F. Sánchez de la Cuesta
Drugs that inhibit TxA2 synthesis are used to reduce platelet aggregation. The aim of this study was to compare the effects of a cyclo‐oxygenase (COX) inhibitor (acetylsalicylic acid, ASA), a thromboxane synthetase (TxS) inhibitor (dazoxiben) and a dual TxS inhibitor and TxA2 receptor blocker (DT‐TX 30) on platelet aggregation and the platelet‐subendothelium interaction in flow conditions. The techniques used in this in vitro study were platelet aggregometry in whole blood, and measurement of platelet thromboxane B2 and prostaglandin E2 production and leucocyte production of 6‐keto‐PGF1α. The platelet‐subendothelium interaction was evaluated in rabbit aorta subendothelium preparations exposed to flowing blood at a shear stress of 800 s−1. Morphometric methods were used to calculate the percentage of subendothelium occupied by platelets. The 50% inhibitory concentration (IC50) of DT‐TX 30 in whole blood was in the range of 10−7 μM (induced with collagen or arachidonic acid) to 10−5 μM (induced with thrombin) or 10−4 (induced with ADP). IC50 values under all experimental conditions were lower with DT–TX 30 than with ASA. For thromboxane B2 the IC50 were: ASA 0.84±0.05 μM, dazoxiben 765±54 μM, DT–TX 30 8.54±0.60 μM. Prostaglandin E2 was inhibited only by ASA (IC50 1.21±0.08 μM). Leucocyte 6‐keto‐PGF1α was inhibited by ASA (IC50 6.58±0.76 μM) and increased by dazoxiben and DT–TX 30. The greatest reduction in percentage subendothelial surface occupied by platelets after blood perfusion was seen after treatment with DT–TX 30 in the range of concentrations that inhibited collagen‐induced platelet aggregation (control group: 31.20±3.8%, DT‐TX 30 at 0.1 μM: 10.71±0.55%, at 1.0 μM: 6.53±0.44%, at 5.0 μM; 1.48±0.07%). All three drugs reduced thrombus formation, although ASA (unlike dazoxiben or DT–TX 30) increased the percentage surface occupied by adhesions. In conclusion, the effect of specific blockage of TxS together with blockage of membrane receptors for TxA2 can surpass the effect of ASA in inhibiting the platelet‐subendothelium interaction in flow conditions.
Diabetes-metabolism Research and Reviews | 2006
José Antonio González-Correa; M.M. Arrebola; A.L. Cansino; J. Muñoz-Marín; D. Ruiz-Villafranca; A. Guerrero; F. Sánchez de la Cuesta; J.P. De La Cruz
The aim of this study was to determine whether the brain tissue of type 1 diabetic animals is more susceptible to damage by hypoxia reoxygenation than healthy animals.